BCRX BioCryst Pharmaceuticals Inc
Company Analysis
Latest News
🔴 BioCryst Pharmaceuticals is trading 4.26% down in pre-market
BioCryst Pharmaceuticals is trading 4.26% down at $9.41 after no clear negative company-specific catalyst was identified for August 26, 2026. - The latest...
🔴 BioCryst Pharmaceuticals is trading 4.37% down today amid broader biotech profit-taking
BioCryst Pharmaceuticals is trading at $9.63, with a -4.37% move on August 20, 2026, amid biotech profit-taking after the previous session’s Moderna-driven...
🟢 BioCryst Pharmaceuticals rises 4.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 BioCryst Pharmaceuticals is trading 5.6% up today in pre-market following stronger-than-expected Q2 results
BioCryst Pharmaceuticals is trading 5.63% up now at $10.50, with continued buying potentially supported by its August 5 earnings report. - The report showed...
🔴 BioCryst Pharmaceuticals is trading 4.15% down today with no clear catalyst identified
BioCryst Pharmaceuticals is trading 4.15% down at $10.15, with no clear company-specific announcement or analyst action identified for August 13, 2026. - The...
🟢 BioCryst Pharmaceuticals is trading 5% up today after guidance rose to $690 million–$715 million
BioCryst Pharmaceuticals is trading $10.32 (+4.88%) after management raised 2026 total revenue guidance. • The move extends the 4.90% gain recorded on August...
🟢 BioCryst Pharmaceuticals is trading 4.05% up today after second-quarter revenue beat and higher 2026 guidance
BioCryst Pharmaceuticals is trading at $9.76, up +4.05%, extending gains after its August 5 second-quarter results. - Revenue reached $218.3 million, beating...
BioCryst's Blowout Quarter Looks Great on Paper — But Can a One-Time Licensing Windfall Justify a Lasting Rally?
Shares jumped 8.6% in pre-market as BioCryst Pharmaceuticals delivered a quarter that topped Wall Street on every line. Revenue of $218.3 million surged 34%...
🟢 BioCryst Pharmaceuticals is trading 4.02% up today after Q2 revenue and EPS beat expectations
BioCryst Pharmaceuticals is trading 4.02% up at $9.44 after its August 5, 2026, second-quarter results beat expectations. - Revenue reached $218.3 million,...
🟢 BioCryst Pharmaceuticals is trading 6.8% up today after beating Q2 estimates and raising its FY26 revenue outlook
BioCryst Pharmaceuticals is trading 6.8% up at $9.63 after reporting better-than-expected second-quarter 2026 results and raising its full-year revenue...
🟢 BioCryst Pharmaceuticals is trading 8.65% up today after beating Q2 estimates and raising its FY26 outlook
BioCryst Pharmaceuticals is trading at $9.80 (+8.65%) following a strong Q2 2026 earnings report and an upward revision to its full-year guidance. • The...
BioCryst Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
BioCryst Pharmaceuticals is expected to report Q2 2026 revenue of $183.28 million and an EPS of $0.14, with its current stock price of $8.98 trading...
🔴 BioCryst Pharmaceuticals is trading 5.6% down today, extending a multi-day slide without a clear catalyst
BioCryst Pharmaceuticals is trading 5.6% down at $8.72 in pre-market, extending its recent multi-day slide despite a lack of fresh company-specific news or...
🔴 BioCryst Pharmaceuticals is trading 6.05% down today without a clear company-specific catalyst
BioCryst Pharmaceuticals is trading at $9.00 (-6.05%) in pre-market, appearing to reverse recent technical momentum in the absence of fresh company-specific...
🟢 BioCryst Pharmaceuticals is trading 5% up today on technical momentum and a broad biotech rally
BioCryst Pharmaceuticals is trading up 4.9% at $9.80 as traders extend a multi-week technical uptrend. • No fresh company-specific news or major catalysts...
🟢 BioCryst Pharmaceuticals is trading 4.9% up today as technical momentum extends multi-week uptrend
BioCryst Pharmaceuticals is trading at $9.80 (4.9%) up in pre-market as technical momentum extends a multi-week uptrend in the absence of fresh company...
🔴 BioCryst Pharmaceuticals is trading 5.2% down
BioCryst Pharmaceuticals is trading at $9.23, down 5.2% from a comparison close of $9.74 during regular trading. This is a price-action follow-up, so a...
JPMorgan Gives BioCryst a Lukewarm Blessing at $12 — But Can a Single Drug Launch Justify the Bet?
Shares of BioCryst Pharmaceuticals surged 7.1% in early trading after JPMorgan resumed coverage with a Neutral rating and a $12 price target, snapping a...
🟢 BioCryst Pharmaceuticals is trading 7.1% up today after JPMorgan resumed coverage with a $12 price target
BioCryst Pharmaceuticals is trading 7.1% up at $10.43 in pre-market sessions after JPMorgan resumed coverage with a Neutral rating and a $12 price target. •...
🟢 BioCryst Pharmaceuticals is trading 5.5% up today as JPMorgan resumes coverage with a $12 price target
BioCryst Pharmaceuticals is trading 5.5% up at $10.27 in after-hours trading, rebounding from recent declines as the company sees renewed analyst focus. •...